Hormonal
Natural products and conventional medications (Statins, Fibrates, Niacin) can inhibit or modulate adipogenesis through specific molecular pathways, offering potential anti-obesity effects.
Current medications like Statins and Fibrates, and various natural products, affect fat cell biology. Statins decrease lipid accumulation and increase small adipocytes. Fibrates increase fatty acid oxidation. Niacin stimulates adipogenesis markers. These mechanisms suggest that existing drugs have off-target effects on fat biology that could be leveraged.
Numerous studies have recently investigated the inhibitory effects of natural products on adipocyte differentiation and lipid accumulation. Possible anti-obesity effects of natural products include the induction of apoptosis, cell-cycle arrest or delayed progression, and interference with transcription factor cascade or intracellular signaling pathways during the early phase of adipogenesis.
Why this rating
Review of preclinical studies; no human clinical outcomes provided.
Source
Adipogenesis as a Potential Anti-Obesity Target: A Review of Pharmacological Treatment and Natural Products
Jelena Jakab et al. · Diabetes Metabolic Syndrome and Obesity · 2021
DOI 10.2147/dmso.s281186
More from this paper
- Obesity is strongly associated with increased oxidative stress, chronic low-grade inflammation, and an increased risk of severe outcomes in infectious diseases like COVID-19.Good
- Inhibiting adipogenesis (the differentiation of preadipocytes into mature adipocytes) via modulation of transcription factors (C/EBP, PPARγ) and signaling pathways (Wnt, AMPK) is a viable therapeutic strategy for preventing or treating obesity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →